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Abstract
Background: Studies investigating a proposed association between multiple sclerosis (MS) and migraine have produced
conflicting results and a great range in the prevalence rate of migraine in MS patients. By meta-analysing all available data
we aimed to establish an overall estimate of any association in order to more accurately inform clinicians and care-givers
about a potential association between MS and migraine.
Methods: Pubmed and EMBASE were searched to identify suitable studies. Studies were included if they were a case-control
study or cohort study in which controls were not reported to have another neurological condition, were available in English,
and specified migraine as a headache sub-type. The odds ratio (OR) of migraine in MS patients vs. controls was calculated
using the inverse variance with random effects model in Review Manager 5.1.
Results: Eight studies were selected for inclusion, yielding a total of 1864 MS patients and 261563 control subjects. We
found a significant association between migraine and MS (OR= 2.60, 95% CI 1.12–6.04), although there was significant
heterogeneity. Sensitivity analysis showed that migraine without aura was associated with MS OR= 2.29 (95% CI 1.14–4.58),
with no significant heterogeneity.
Conclusions: MS patients are more than twice as likely to report migraine as controls. Care providers should be alerted to
ask MS patients about migraine in order to treat it and potentially improve quality of life. Future work should further
investigate the temporal relationship of this association and relationship to the clinical characteristics of MS.
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Introduction
Multiple sclerosis (MS) is an inflammatory disease of the central
nervous system (CNS) characterized by myelin loss, varying
degrees of axonal pathology, and progressive neurological
dysfunction. The clinical features of MS encompass an extremely
wide range of neurological symptoms but migraine is not typically
included [1]. Migraine is a common chronic debilitating condition,
with an estimated 1-year period prevalence of 11.7%, which
reduces the quality of life in many sufferers [2,3].
Within Europe, migraine has a high economic impact, with
headaches (including migraine) estimated to cost J43.5 billion
per capita in 2010 [4]. MS and migraine have a number of
demographic similarities including a female preponderance and
relatively young age at onset [5,6]. Epidemiological similarities
also exist, as both conditions have a higher prevalence in
Caucasian as compared to African or Asian populations [7,8].
In 1952 Compston and McAlpine found that 2% of MS
sufferers experienced migraine within 3 months of MS onset [9].
This finding stimulated further studies but limitations, including
small sample sizes, has resulted in conflicting results and a great
range in the prevalence rate of migraine in MS patients [10–18].
In this meta-analysis we sought to provide an overall estimate of
the relationship between MS and migraine by comparing the
occurrence of migraine in MS patients vs. controls in order to
accurately inform clinicians.
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Methods
Article Search
Pubmed was searched by JP and AEH for abstracts using the
terms (‘‘multiple sclerosis’’[MeSH Terms] OR (‘‘multiple’’[All
Fields] AND ‘‘sclerosis’’[All Fields]) OR ‘‘multiple sclerosis’’[All
Fields]) AND (‘‘migraine disorders’’[MeSH Terms] OR (‘‘mi-
graine’’[All Fields] AND ‘‘disorders’’[All Fields]) OR ‘‘migraine
disorders’’[All Fields] OR ‘‘migraine’’[All Fields]) and (‘‘multiple
sclerosis’’[MeSH Terms] OR (‘‘multiple’’[All Fields] AND
‘‘sclerosis’’[All Fields]) OR ‘‘multiple sclerosis’’[All Fields])
AND (‘‘headache’’[MeSH Terms] OR ‘‘headache’’[All Fields]).
EMBASE was searched for abstracts using the terms ‘‘multiple
sclerosis [All fields] AND migraine [All fields]. No limitations or
time period restrictions were applied; the latest search was
undertaken on the 17th December 2011. We were not familiar
with any study currently in progress to be considered for
inclusion. Published conference abstracts were eligible for
inclusion and so were both prospective and retrospective studies.
Studies were subsequently excluded if they were not a case-
control study or cohort study, if the article was not available in
English, or if migraine was not specified as a headache sub-type.
Studies where controls had other neurological conditions were
also excluded. The abstracts of the resulting articles were hand-
searched in order to select studies. Attempts to identify further
articles were done by searching the references of the studies. Data
on study type, raw numbers of MS patients and controls who had
and had not experienced migraine and their sex; diagnostic
criteria of MS and migraine used; method of migraine
ascertainment; source of cases and controls; age range and mean
age of patients and controls; MS patient subtype, mean diseases
duration and median EDSS score was extracted independently
from included articles. Any discrepancy on the suitability for
inclusion of a study between the authors was resolved by
consulting a third author (SVR).
Statistical Analysis
The inverse variance model in Review Manager 5.1 was used to
calculate the overall odds ratio (OR), 95% confidence interval
(95% CI) and test statistic for the relationship. Statistical
significance was set at p,0.05. Statistical heterogeneity of studies
was assessed through the calculation of Tau2 and I2. A random
effects model was applied unless the I2 was #25% in which case a
fixed effects model would be used [19]. In attempting to dissipate
any heterogeneity, sensitivity analysis was done by excluding
individual studies to see if there was a notable reduction in
heterogeneity and further, subgroup analysis was performed on
studies which differentiated between migraine with and without
aura. Generation of a funnel plot and the Egger p-value allowed
determination of the potential publication bias of included studies.
Further, the quality of the studies was assessed using the
Newcastle-Ottawa Scale (NOS).
Table 2. Newcastle-Ottawa Scale (NOS) assessment of the quality of the studies.
Study Selection (max 4 3) Comparability (max 2 3) Exposure (max 3 3)
Katsiari 2011 33 33 3
Kister 2010 33 33 3
Kister 2012 3333 33 33
Nicoletti 2008 333 33 3
Putzki 2009 333 33 3
Vacca 2007 3333 33 3
Watkins 1969 333 33 33
Zorzon 2003 3333 33 33
doi:10.1371/journal.pone.0045295.t002
Figure 1. Forest plot of comparison: MS patients vs. control, outcome: migraine.
doi:10.1371/journal.pone.0045295.g001
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Results
Included Studies
Our Pubmed search initially yielded 654 studies (of which some
studies appeared under more than one search term) and the
EMBASE search 705 studies. In total, 8 studies were selected for
inclusion according to the described inclusion criteria [11–18],
yielding a total of 1864 MS patients and 261563 control subjects.
However, it should be noted that Kister et al 2010 and Nicoletti et
al 2008 used historical controls [15,18]. Information about the
included studies can be found in table 1 and the assessed quality
of each study using NOS is indicated in table 2.
Migraine in MS Patients vs. Control
Migraine was more common in MS patients than controls.
The overall OR upon inclusion of all 8 studies was 2.60 (95% CI
1.12–6.04), fig 1, however, significant statistical heterogeneity
was identified (I2 = 97% Chi2 = 247.10, P,0.00001). Publica-
tion bias assessment is shown using a funnel plot, fig 2. No
selective reporting of outcomes was found for any study when
comparing methods of studies to results. There was no
significant indication of publication bias, Egger p-value = 0.64.
The results of subgroup analyses of studies investigating
migraine with and without aura showed a significant co-morbid
association between MS and migraine without aura (OR= 2.29
(CI = 1.14–4.58)) without any significant heterogeneity (Table 3
and Figure 3).
Discussion
This meta-analysis has shown that there is a significant
association between migraine and MS, with MS patients being
more than twice as likely to report migraine as controls.
Limitations of this study include the nature of the studies
included and study heterogeneity [20]. Of note, in subgroup
analyses, migraine without aura was significantly increased in
patients with MS (OR=2.29 (CI = 1.14–4.58)) without any
significant heterogeneity. The heterogeneity may be in part
explained by variation in the demographic characteristics (as
shown in table 1), recall/reporting/interviewer bias of migraine
in some studies as this data was largely collected by question-
naire/interview and ascertainment/selection bias of MS patients
and controls. As indicated in Table 2, we found some
discrepancy in the quality of the studies and the potential for
bias. Bias may result in an over or under-estimation of ORs
depending on whether the bias is differential or non-differential
with respect to MS patients and controls. It can be speculated
that MS patients are more likely to be in contact with a
Figure 2. Funnel plot of included studies.
doi:10.1371/journal.pone.0045295.g002
Table 3. Odds ratio and 95% confidence intervals for subgroup studies.
Subgroup of studies Odds ratio with 95% CI P-value Number of studies Heterogeneity
Migraine with aura 0.8 (0.29–2.16) P = 0.65 3[16–18] Tau2 = 0.34; Chi2 = 3.55, df = 2
(P = 0.17); I2 = 44%
Migraine without aura 2.29 (1.14–4.58) P = 0.02 3[16–18] Tau2 = 0.21; Chi2 = 4.62, df = 2
(P = 0.10); I2 = 57%
Abbreviations: CI = confidence interval, df = degree of freedom. Tau2 estimates the between-study variance and I2 describes the proportion of variation estimated to be
due to heterogeneity.
doi:10.1371/journal.pone.0045295.t003
Multiple Sclerosis and Migraine Relationship
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neurologist and may thus be more likely to report migraine and/
or have migraine detected, resulting in an overestimated OR.
Similarly, an MS patient may be more attentive to the frequency
and severity of migraine.
Whereas the occurrence of migraine without aura but not
migraine with aura was found to be significantly more frequent in
MS patients, it is plausible that small sample sizes in studies
investigating migraine with aura meant there was insufficient
power to detect significance.
Further, the study by Rolak and Brown, which was not included
in this investigation as the controls had neurological disorders,
found migraine reported in 22/104 MS patients vs. in 10/100
control neurological patients, OR 2.41 (CI 1.08- 5.40) [10].
The mechanism behind any association between MS and
migraine remains to be determined but a number of hypotheses
exist. Nicoletti et al compared the age of onset of both
conditions which was 33.6 -+10.8 years for MS and 19.5+- 7.4
years for migraine [18]. Since migraine often precedes MS by
numerous years, as also shown by Kister et al, another potential
explanation is that migraine could be a potential risk factor for
MS [11]. However, cortical demyelination has been shown to
accelerate cortical spreading depression in rodent models of
autoimmune induced cortical demyelination, a key aspect in
migraine pathophysiology [21]. Migraine may therefore result
from early MS lesions. Importance of lesion location in MS
patients has also been suggested following observations that
lesions within the midbrain are more commonly associated with
co-morbid migraine in MS patients. This may be explained by
the presence of the periaqueductal gray matter (PAG) within
the midbrain which is suspected to have a role in migraine
aetiology [22,23].
Immune therapies used to treat MS may also a have a role as
evidence for a migraine-inducing role of interferon beta exists
[24], however, immune therapies could only ever provide a small
part of the complete explanation due to the fact that migraine
often precedes MS. Interferon beta treatment is also thought to
worsen pre-existing migraine, suggesting it may not be implicated
in the aetiology of the migraine itself [25]. Notably, evidence
suggests that the other disease modifying therapies glatiramer
acetate and natalizumab do not appear to worsen migraine, and
indeed some patients may want to take this into consideration as
switching from interferon beta may help reduce both frequency
and severity of migraine [26–27]. Furthermore, stress and
anxiety, which often accompany MS, are thought to be very
likely causes of increased migraine frequency and chronification
[28]. One further suggestion is that instead of one condition
causing the other, both conditions have a common pathway in
their underlying cause.
Before any of the above hypotheses can be confirmed, more
studies specifically investigating whether MS precedes migraine or
vice versa would be necessary to determine the temporal
relationship of the demonstrated association and clarify whether
migraine is as a risk-factor, co-morbidity or symptom of MS.
Regardless, the key aspect of this study is the potentially
underappreciated finding of migraine being more common in
MS patients and as a major potential cause of poorer quality of
life, it should be actively looked for and treated.
Author Contributions
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Figure 3. Forest plot of comparison: MS patients vs. control.
doi:10.1371/journal.pone.0045295.g003
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